Take a look at the FDA Application Approvals 2000-2008 visualization (created by user mktlgcs) over at IBM’s Many Eyes to get an aerial view on the US. pharmaceutical industry.
Friend Dan Erlanson (Co-Editor in Chief of the niche and smart Fragment-based Drug Design blog Practical Fragments) sent me this story on the recession proof business model of a biotech company called BioBlocks and his founder medical chemist Peter Pallai: Approximately one out of 5,000 compounds pass an initial screen, hit the designated biological target,… Continue reading BioBlocks: outsourcing biotech, one block at a time
There is a nice initiative now in Budapest dedicated to the present and future of high technology: a new private university momentarily dubbed as Aquincum Institute of Technology (AIT) will be built near to the Graphisoft Park in Óbuda (Aquincum) concentrating on competitive information-/biotechnology (mainly bioinformatics) education and entrepreneurship. The main instigator of the project… Continue reading Aquincum Institute of Technology, Budapest, IT & BT shaking hands
Andrew Chen, founder of CoNotes said that to my mailbox: “I’m basically trying to solve the problem that startups have in hiring the right people. A lot of it has to do with marketing (it’s hard for startups to get prominence over big named companies particularly in university settings), but also fit.“ And that is… Continue reading Do you want a startuppy job: ask CoNotes or not!
The Wall Street Journal Patent Board Biotechnology Scorecard was published this week in which biotech companies & private research firms are grouped by their Patent Board science strength ranking “which is based on the scale, quality, impact, and nearness to core science of a company’s patent-based intellectual property”. What I found interesting at the first… Continue reading Patent Board science strength of biotech firms in WSJ
Billionaire investor Carl Icahn (72) recently made the bloglines with his energetic position on the Microsoft – Yahoo deal. He has a blog too or at least it is coming soon since 01/31. /Having a blog for more than 3 months without any content is kinda equivalent with planning to sign up for Twitter but… Continue reading 80 is the new 50 so Carl Icahn has a blog without content.
from my mailbox: Science-Business eXchange aka SciBX is a new publication from the makers of Nature and BioCentury that aims to improve the translation of today’s science into tomorrow’s products for the diagnosis, treatment and prevention of disease.